

Francesca Galuppini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3949349/publications.pdf>

Version: 2024-02-01

52
papers

1,166
citations

361045

20
h-index

414034

32
g-index

52
all docs

52
docs citations

52
times ranked

1930
citing authors

#	ARTICLE	IF	CITATIONS
1	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 939-944.	1.4	3
2	Can ultrasensitive thyroglobulin immunoassays avoid the need for ultrasound in thyroid cancer follow-up?. Endocrine, 2022, 75, 837-845.	1.1	2
3	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Frontiers in Endocrinology, 2022, 13, 834075.	1.5	5
4	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. Pathology Research and Practice, 2022, 233, 153872.	1.0	1
5	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	1.1	3
6	The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. Diagnostics, 2021, 11, 339.	1.3	46
7	The role of the size in thyroid cancer risk stratification. Scientific Reports, 2021, 11, 7303.	1.6	2
8	Polydatin Prevents Calcium Pyrophosphate Crystal-Induced Arthritis in Mice. Nutrients, 2021, 13, 929.	1.7	7
9	miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related Therapeutic Perspectives in Esophageal Carcinoma. International Journal of Molecular Sciences, 2021, 22, 3640.	1.8	13
10	The impact of recent next generation sequencing and the need for a new classification in gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 50-51, 101730.	1.0	18
11	Serum miR-375 for Diagnostic and Prognostic Purposes in Medullary Thyroid Carcinoma. Frontiers in Endocrinology, 2021, 12, 647369.	1.5	12
12	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines, 2021, 9, 318.	1.4	7
13	Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1897-1904.	1.2	7
14	MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives. Cells, 2021, 10, 955.	1.8	8
15	Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1085-1090.	1.4	12
16	The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI). International Journal of Molecular Sciences, 2021, 22, 3826.	1.8	12
17	A KRAS-responsive long non-coding RNA controls microRNA processing. Nature Communications, 2021, 12, 2038.	5.8	30
18	The histomorphological and molecular landscape of colorectal adenomas and serrated lesions. Pathologica, 2021, 113, 218-229.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. International Journal of Molecular Sciences, 2021, 22, 9950.	1.8	11
20	Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows. Frontiers in Endocrinology, 2021, 12, 754565.	1.5	9
21	<p>Medullary Thyroid Carcinoma in a Patient with MEN 1 Syndrome. Case Report and Literature Review</p>. OncoTargets and Therapy, 2020, Volume 13, 7599-7603.	1.0	1
22	Prognostic significance of the sum of the diameters of single foci in multifocal papillary thyroid cancer: the concept of new-old tumor burden. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882096432.	1.4	3
23	First proof of association between autoimmune polyglandular syndrome and multiple endocrine neoplasia in humans. Endocrine Journal, 2020, 67, 929-934.	0.7	2
24	Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 241-248.	1.4	9
25	Gastritis: update on etiological features and histological practical approach. Pathologica, 2020, 112, 153-165.	1.3	24
26	<p>Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma</p>. Cancer Management and Research, 2019, Volume 11, 7845-7855.	0.9	6
27	Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell International, 2019, 19, 209.	1.8	116
28	Current role of non-coding RNAs in the clinical setting. Non-coding RNA Research, 2019, 4, 82-85.	2.4	25
29	Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients. International Journal of Endocrinology, 2019, 2019, 1-7.	0.6	8
30	F-actin dynamics regulates mammalian organ growth and cell fate maintenance. Journal of Hepatology, 2019, 71, 130-142.	1.8	56
31	Periodontal Injection of Lipopolysaccharide Promotes Arthritis Development in Mice. Inflammation, 2019, 42, 1117-1128.	1.7	12
32	Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer. Human Pathology, 2019, 85, 145-151.	1.1	51
33	Unique Case of a Large Indolent Medullary Thyroid Carcinoma: Time to Reconsider the Medullary Thyroid Adenoma Entity?. European Thyroid Journal, 2019, 8, 108-112.	1.2	5
34	Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology. European Journal of Endocrinology, 2019, 181, 1-11.	1.9	39
35	The rising incidence of papillary thyroid cancer: More cancers or more assessments?. Indian Journal of Cancer, 2019, 56, 183.	0.2	5
36	The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes. Thyroid, 2018, 28, 96-103.	2.4	40

#	ARTICLE	IF	CITATIONS
37	MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. Pathology Research and Practice, 2018, 214, 835-839.	1.0	26
38	p53 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. Histopathology, 2017, 71, 470-474.	1.6	27
39	Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. Histopathology, 2017, 71, 769-777.	1.6	29
40	Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components. Pathology Research and Practice, 2017, 213, 1010-1013.	1.0	6
41	MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical pathological features and outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 651-658.	1.4	25
42	BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. Histopathology, 2017, 71, 1008-1011.	1.6	8
43	Antibiotic-induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice. British Journal of Pharmacology, 2017, 174, 3623-3639.	2.7	82
44	Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit. Frontiers in Endocrinology, 2017, 8, 273.	1.5	31
45	Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma. International Journal of Endocrinology, 2017, 2017, 1-9.	0.6	23
46	BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1531-1539.	1.4	12
47	Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. PLoS ONE, 2016, 11, e0156044.	1.1	45
48	The PDCD4/miR-21 pathway in medullary thyroid carcinoma. Human Pathology, 2015, 46, 50-57.	1.1	66
49	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. Oncotarget, 2015, 6, 32104-32114.	0.8	23
50	Synchronous medullary, papillary and follicular carcinomas in the same thyroid: case report and review of literature. Updates in Surgery, 2013, 65, 329-332.	0.9	7
51	PDCD4 expression in thyroid neoplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 95-100.	1.4	22
52	MicroRNA Profiles in Familial and Sporadic Medullary Thyroid Carcinoma: Preliminary Relationships with RET Status and Outcome. Thyroid, 2012, 22, 890-896.	2.4	116